The Esketamine Evidence for Postpartum Depression Is About the Delivery Room, Not Your Clinic
Ketamine given around a C-section eased early postpartum depression symptoms, anesthesiologists reported this month at ANESTHESIOLOGY 2026. It is a real result. It is also not about anything an outpatient ketamine clinic does.
The inquiries you decline still cost staff time to answer well. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The new finding | 6 trials, 1,832 women, ketamine at elective C-section, EPDS effect of -0.36 |
| The setting | Operating room and recovery, hours after delivery, to prevent symptoms |
| The wider literature | Most esketamine PPD trials sit in anesthesiology journals, not psychiatry ones |
| The comparison | A network meta-analysis puts esketamine at -0.63 against placebo |
| What is approved | Brexanolone since 2019 and zuranolone since 2023 |
| What is not | Esketamine carries no postpartum depression indication |
Where the Trials Actually Happened
This is the fact that reframes everything else.
Search the published esketamine work on postpartum depression and the same words keep appearing. Cesarean. Labor analgesia. Perioperative. Prophylactic. Prevention.
One example. A multicentre randomized trial of prophylactic esketamine in first-time mothers appeared this year in the European Journal of Anaesthesiology, from an obstetrics and gynecology hospital.
That is where this literature lives. An anesthesiologist gives a dose in an operating room, hours after birth, to stop symptoms from forming.
It is not a woman at eight weeks postpartum, already unwell, sitting in an infusion chair.
What the Anesthesiologists Found
The new meta-analysis pooled six randomized trials covering 1,832 women having elective cesareans.
Women given ketamine or esketamine during or after surgery scored lower on the Edinburgh Postnatal Depression Scale between days 3 and 14.
The effect was a standardized mean difference of -0.36, which is small to moderate.
The lead author was careful in the release. It is too early, he said, to claim that ketamine prevents clinically diagnosed postpartum depression.
Two weeks of symptom scores after surgery is a narrow window. Postpartum depression is diagnosed and lived over months.
Ranking the Options, With a Caveat
A separate network meta-analysis published in Psychiatry Research puts the drugs side by side.
It pooled 18 randomized trials covering 1,722 patients and compared each intervention against placebo on symptom severity.
Esketamine came in at a standardized mean difference of -0.63, with a confidence interval running from -0.89 to -0.37. That is a real signal and a reasonably tight one.
Brexanolone was the only intervention with a statistically significant result for remission. It also showed an unfavorable acceptability signal on all-cause discontinuation, and zuranolone was associated with more adverse events.
Saffron Finished First, Which Should Give You Pause
The top-ranked intervention in that analysis was saffron, at -1.07. Fluoxetine came second at -0.95.
A botanical preparation outranking fluoxetine is a signal about the trial pool, not a discovery about saffron.
The authors say so themselves. The networks are sparse, certainty is mostly low to moderate, and the rankings should be read as exploratory.
So the usable finding is that esketamine shows a measurable effect. The ordering is not something to quote at a patient.
How a trial measures its outcome shapes the answer. We looked at that problem in ketamine research more broadly.
Two Drugs Are Approved for This. Esketamine Is Not One
Brexanolone has carried a postpartum depression indication since 2019. It runs as a 60-hour intravenous infusion in a certified monitored setting, with a boxed warning for excessive sedation.
Zuranolone followed in August 2023 as the first oral option, taken at home for 14 days.
Esketamine carries neither. Its indications are treatment-resistant depression, and depressive symptoms in adults with major depression and acute suicidal ideation or behavior, which we covered in what that second indication involves.
Postpartum depression is not on that label.
Answering the Call
Clinics do field these inquiries, and a straight answer is better than either enthusiasm or a brush-off.
What is supportable: ketamine and esketamine show measurable effects on postpartum depressive symptoms in randomized trials. The question is being studied seriously.
What is not: that an outpatient infusion is an evidence-based treatment for established postpartum depression. The trials behind those numbers were mostly run in operating rooms.
Where to point: two approved medications exist, and a patient who wants an indicated treatment should hear about them.
What a clinic can still treat: a diagnosed major depressive episode is a different matter. Documenting that distinction is what keeps the chart defensible.
That documentation habit is the first item in our list of 8 gaps that create malpractice exposure.
Prevention Is Not Treatment
The two words get used interchangeably in coverage of this research, and they describe different medicine.
Preventing symptoms during surgery and treating an established illness months later are separate questions. They have separate evidence, in separate journals.
Right now only one of them has been studied properly, and it is not the one a ketamine clinic performs.
The same care applies to other unapproved uses patients ask about. We set that out for functional neurological symptoms.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical advice. Esketamine is not approved by the FDA for postpartum depression. Anyone experiencing postpartum depression should speak with a clinician, and in a crisis can call or text 988.
